Inthera Bioscience Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11.2M

  • Investors
  • 5

Inthera Bioscience General Information

Description

Developer of targeted small molecule therapies designed to treat solid tumors. The company's therapies are focused on the development of novel oral agents blocking aberrant cell signaling in solid tumors by leveraging a proprietary platform to rationally design protein-protein interaction inhibitors, enabling the medical community to improve outcomes involving cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • Schärenmoosstrasse 77
  • 8052 Zurich
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inthera Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 26-Jun-2018 $11.2M 000.00 000.00 Completed Pre-Clinical Trials
2. Seed Round 14-Dec-2015 00.000 00.000 Completed Product Development
1. Seed Round 30-Apr-2014 $226K $226K 00.000 Completed Generating Revenue
To view Inthera Bioscience’s complete valuation and funding history, request access »

Inthera Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 000.00 000.00 00 000.00 00.000
Seed 00,000 000.00 000.00 00 000.00 0.000
Seed 277,776 $7.98 $7.98 1x $7.98 20.84%
Ordinary 25,000 $9.34 $9.34 1x $9.34 1.88%
To view Inthera Bioscience’s complete cap table history, request access »

Inthera Bioscience Patents

Inthera Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200308139-A1 Oxopiperazine derivatives Pending 15-Dec-2017 0000000000
US-20190185449-A1 Oxopiperazine derivatives Granted 15-Dec-2017 0000000000
US-10710975-B2 Oxopiperazine derivatives Active 15-Dec-2017 0000000000 00
AU-2018386327-A1 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer Pending 15-Dec-2017 0000000000
JP-2021506973-A 1- (piperidinocarbonylmethyl) -2-oxopiperazin derivative for cancer treatment Pending 15-Dec-2017 C07D401/06
To view Inthera Bioscience’s complete patent history, request access »

Inthera Bioscience Executive Team (7)

Name Title Board Seat Contact Info
Ulrich Kessler Co-Founder & Co-Chief Executive Officer
Bernd Hentsch Ph.D Chief Development Officer
Paul Cloos Ph.D Chief Scientific Officer
Ralph Lindemann Ph.D Co-Chief Scientific Officer
Paramjit Arora Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

Inthera Bioscience Board Members (9)

Name Representing Role Since
Anker Lundemose Ph.D Self Board Member 000 0000
Christian Uhrich M Ventures Board Member 000 0000
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Klaus Schollmeier Ph.D Self Chairman 000 0000
Mark Krul Ph.D Aglaia Oncology Funds Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Inthera Bioscience Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aglaia Oncology Funds Venture Capital Minority 000 0000 000000 0
Eva Capital Accelerator/Incubator Minority 000 0000 000000 0
Microsoft for Startups Accelerator/Incubator Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
To view Inthera Bioscience’s complete investors history, request access »